Risk of fractures of two antidiabetics
The unwanted effects of two drugs for diabetes, acts (rosiglitazone) and avandia (pioglitazone), are subject to intense research.Two studies released this week add new data for the debate.The first one, presented at the Congress of the American Diabetes Society held in New Orleans (United States), analyzed in more than 144,000 patients the use of these products compared to other older drugs for diabetes.It was found that the ingestion of Avandia or acts can increase the risk of fractures by 43%.
The second work, published in the 'online' edition of 'The Lancet', concludes that the use of Avandia along with other antidiabetics (metformin or sulfonylureas) does not raise the risk of cardiovascular or death disease, but heart failure and heart failure and, especially in women, fractures.The authors indicate that their results will help advise or restrict their administration in certain patients.
At the moment, the doctors have the last word.Despite cardiovascular and fracture risk, the power of these drugs to control the amount of blood glucose is much higher than other antidiabetic agents.
